z-logo
Premium
Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs . carbon dioxide laser in treatment of xanthelasma palpebrarum
Author(s) -
Mourad Basma,
Elgarhy Lamia H.,
Ellakkawy HebaAlla,
Elmahdy Nageh
Publication year - 2015
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12148
Subject(s) - tolerability , carbon dioxide laser , cauterization , medicine , erythema , trichloroacetic acid , dermatology , ablation , surgery , chemistry , adverse effect , laser , chromatography , laser surgery , physics , optics
Summary Background There are numerous methods currently available for the management of xanthelasma. These include surgical excision, laser ablation using a variety of lasers and chemical cauterization. However, each method of treatment is associated with particular limitations and side effects. Objectives To assess the clinical efficacy and tolerability of different concentrations of topical trichloroacetic acid (TCA) vs . carbon dioxide laser in the treatment of patients with xanthelasma palpebrarum. Methods Thirty patients with xanthelasma palpebrarum were classified into four groups, treated by TCA 35%, 50%, 70%, and CO 2 laser, respectively. Lipid profile was estimated for all patients. Results Both TCA peeling 70% and carbon dioxide laser ablation showed more significant clinical efficacy and tolerability with least number of sessions in the treatment of xanthelasma palpebrarum than 50% and 35% TCA peeling. Post‐therapy erythema and hypopigmentation were more with TCA 70%. Post‐therapy hyperpigmentation was more with TCA (50%). There was a significant improvement in patients with normal lipid profile than those with abnormal profile. Conclusion Both TCA peeling 70% and carbon dioxide laser ablation are highly effective and well tolerated with least number of sessions in the treatment of xanthelasma palpebrarum.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here